Metastatic Head-and-neck Squamous-cell Carcinoma Clinical Trial
Official title:
Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor: A Single-Arm, Phase 2 Trial
The primary hypothesis is that the objective response rate (ORR) with nab-paclitaxel and nivolumab will be significantly higher than the historical control (ORR 30%). The KEY secondary hypothesis is that the median PFS with nab-paclitaxel and nivolumab will be significantly longer than the historical control (median PFS 3.6 months).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02119559 -
Circulating Tumor Cells as an Early Predictive head-and -Neck Squamous-cell Carcinoma
|
N/A | |
| Recruiting |
NCT05980000 -
Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05047094 -
A Safety and Efficacy Study for Combinational Treatment of DaRT and Check Point Inhibitor for Recurrent Unresectable or mHNSCC
|
N/A | |
| Recruiting |
NCT04375384 -
Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
|
Phase 2 | |
| Recruiting |
NCT06064877 -
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
|
Phase 3 | |
| Recruiting |
NCT04454489 -
Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition
|
Phase 2 | |
| Recruiting |
NCT06239220 -
PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
|
Phase 2 | |
| Active, not recruiting |
NCT04305795 -
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT02449681 -
Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin
|
Phase 2 |